Eloralintide

ELORALINTIDE (LY3841136)

Selective Amylin Receptor Agonist | Metabolic & Weight-Management Research

Eloralintide, also known as LY3841136, is an investigational long-acting peptide designed to selectively activate the amylin-1 receptor (AMY1R). It is being studied for its effects on appetite regulation, satiety, energy intake, body weight, and metabolic health.

Unlike GLP-1 receptor agonists, Eloralintide works primarily through the amylin signaling pathway, making it particularly interesting for research involving alternative or complementary mechanisms of metabolic regulation.

Areas of Research

• Appetite and satiety signaling
• Reduced caloric intake
• Body-weight and fat-mass regulation
• Metabolic health
• Amylin-receptor signaling
• Combination research with incretin-based compounds

Research Dosing Studied

Human clinical research has evaluated once-weekly subcutaneous administration. Phase 2 research included weekly target doses of 1 mg, 3 mg, 6 mg, and 9 mg, as well as dose-escalation protocols progressing to 9 mg.

Why Researchers Are Interested

Eloralintide preferentially activates AMY1R compared with the calcitonin receptor and AMY3R. Early clinical research has demonstrated reductions in body weight and food intake, supporting continued investigation of selective amylin signaling as a distinct approach to metabolic research.

Research Use Only

Eloralintide remains an investigational compound and has not been approved as a medication for general clinical use. Research protocols should be based on appropriate published literature and applicable laboratory standards.